Association of plasma CD163 concentration with de novo-onset chronic graft-versus-host disease.

Publication Type:

Journal Article


Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2017)


Chronic graft-versus-host disease (cGVHD) is the leading cause of long-term morbidity and mortality after allogeneic hematopoietic cell transplantation. In order to identify prognostic plasma proteins associated with de novo or quiescent-onset cGVHD, we performed a discovery and validation proteomic study. The total study cohort included 167 consecutive patients who had no clinical evidence of GVHD under minimum glucocorticoid administration, and had available plasma samples obtained at 80±14 days after transplantation. We first used high-throughput mass spectrometry to screen pooled plasma using 20 cases with subsequent cGVHD and 20 controls without it, and identified 20 candidate proteins. We then measured 12 of the 20 candidates by enzyme-linked immunosorbent assays on the same individual samples and identified 4 proteins for further verification (LGALS3BP, CD5L, CD163 and TXN for de novo onset, and LGALS3BP and CD5L for quiescent onset). The verification cohort included 127 remaining patients. The cumulative incidence of de novo-onset cGVHD was higher in patients with higher plasma soluble CD163 concentrations at day 80 than those with lower concentrations (75% versus 40%, P=0.018). The cumulative incidence of de novo or quiescent-onset cGVHD did not differ statistically according to concentrations of the three other proteins at day 80. CD163 is a macrophage scavenger receptor and is elevated in oxidative conditions. These results suggest that monocyte or macrophage activation or increased oxidative stress may contribute to the pathogenesis of cGVHD.